

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

27 Jul 2026

### Efficacy and Safety of Topical Metformin 30% in the Treatment of Melasma Compared to Triple Combination Cream(0.05% tretinoin, 2% hydroquinone, 0.01% fluocinolone acetonide)

#### Protocol summary

##### Study aim

To evaluate and compare the efficacy of topical metformin 30% versus triple combination cream in treatment of melasma.

##### Design

Community based, parallel group, double blind, randomized control trial

##### Settings and conduct

Participants of study meeting the inclusion criteria will be allotted two groups by lottery method of randomization. Melasma severity and Quality of life will be recorded as MASI score and MelasQoL respectively at the base line. Group A will receive topical metformin 30% cream at night while group B will receive topical triple combination cream at night. Participants will be blinded to what treatment they are getting. Both the groups will be assessed at 4 week, 8 week and 12 weeks and MASI, melasQoL, patient satisfaction and adverse effects will be recorded by an independent assessor. Participants will be assessed again at 16 week to assess recurrence. Study will be conducted at CMH, Quetta, Pakistan.

##### Participants/Inclusion and exclusion criteria

Inclusion Criteria- Adults aged 18- 60 with melasma, Fitzpatrick skin type III-V, no other melasma Exclusion Criteria: Use of photosensitizing drugs like phenytoin, tetracycline etc, pregnancy, lactation, renal disease, liver disease, history of recent laser treatment or hypersensitivity to metformin or triple combination cream

##### Intervention groups

Group A- topical metformin 30% cream at night Group B- topical triple combination cream at night

##### Main outcome variables

Primary Outcomes- Safety and efficacy Secondary outcomes- Quality of life, patient satisfaction, recurrence

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20210823052264N9**

Registration date: **2024-09-21, 1403/06/31**

Registration timing: **prospective**

Last update: **2024-09-21, 1403/06/31**

Update count: **0**

##### Registration date

2024-09-21, 1403/06/31

##### Registrant information

##### Name

Najia Ahmed

##### Name of organization / entity

PNS shifa

##### Country

Pakistan

##### Phone

+92 81 2864092

##### Email address

najiaomer@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2024-09-24, 1403/07/03

##### Expected recruitment end date

2025-01-24, 1403/11/05

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

|                                               |                                                                                                                                                                                                                                                |                                                                                             |
|-----------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| empty                                         |                                                                                                                                                                                                                                                | <u>1</u>                                                                                    |
| <b>Scientific title</b>                       | Efficacy and Safety of Topical Metformin 30% in the Treatment of Melasma Compared to Triple Combination Cream(0.05% tretinoin, 2% hydroquinone, 0.01% fluocinolone acetonide)                                                                  | <b>Ethics committee</b>                                                                     |
|                                               |                                                                                                                                                                                                                                                | <b>Name of ethics committee</b>                                                             |
|                                               |                                                                                                                                                                                                                                                | Institutional ethical review board (IERB) certificate - CMH Quetta                          |
|                                               |                                                                                                                                                                                                                                                | <b>Street address</b>                                                                       |
|                                               |                                                                                                                                                                                                                                                | Quetta                                                                                      |
|                                               |                                                                                                                                                                                                                                                | <b>City</b>                                                                                 |
|                                               |                                                                                                                                                                                                                                                | Quetta                                                                                      |
|                                               |                                                                                                                                                                                                                                                | <b>Postal code</b>                                                                          |
|                                               |                                                                                                                                                                                                                                                | 08762                                                                                       |
|                                               |                                                                                                                                                                                                                                                | <b>Approval date</b>                                                                        |
|                                               |                                                                                                                                                                                                                                                | 2024-09-24, 1403/07/03                                                                      |
|                                               |                                                                                                                                                                                                                                                | <b>Ethics committee reference number</b>                                                    |
|                                               |                                                                                                                                                                                                                                                | CMH QTA-IERB /38/2024                                                                       |
| <b>Public title</b>                           | Efficacy and Safety of Topical Metformin 30% in the Treatment of Melasma Compared to Triple Combination Cream(0.05% tretinoin, 2% hydroquinone, 0.01% fluocinolone acetonide)                                                                  | <b>Health conditions studied</b>                                                            |
| <b>Purpose</b>                                | Treatment                                                                                                                                                                                                                                      | <u>1</u>                                                                                    |
| <b>Inclusion/Exclusion criteria</b>           |                                                                                                                                                                                                                                                | <b>Description of health condition studied</b>                                              |
| <b>Inclusion criteria:</b>                    | Fitzpatrick skin types III- V No other melasma treatments in the last 6 weeks                                                                                                                                                                  | melasma                                                                                     |
| <b>Exclusion criteria:</b>                    | Use of systemic photosensitizing drugs like phenytoin, tetracycline etc Pregnant or breastfeeding women Liver disease/ renal disease History of recent laser treatment or hypersensitivity to metformin or TCC.                                | <b>ICD-10 code</b>                                                                          |
| <b>Age</b>                                    | From <b>18 years</b> old to <b>60 years</b> old                                                                                                                                                                                                | L81.1                                                                                       |
| <b>Gender</b>                                 | Both                                                                                                                                                                                                                                           | <b>ICD-10 code description</b>                                                              |
|                                               |                                                                                                                                                                                                                                                | Chloasma                                                                                    |
| <b>Phase</b>                                  | 3                                                                                                                                                                                                                                              | <b>Primary outcomes</b>                                                                     |
| <b>Groups that have been masked</b>           | <ul style="list-style-type: none"> <li>Participant</li> <li>Data analyser</li> </ul>                                                                                                                                                           | <u>1</u>                                                                                    |
| <b>Sample size</b>                            | Target sample size: <b>60</b>                                                                                                                                                                                                                  | <b>Description</b>                                                                          |
| <b>Randomization (investigator's opinion)</b> | Randomized                                                                                                                                                                                                                                     | Change in MASI scores from baseline                                                         |
| <b>Randomization description</b>              | Two groups are made by simple lottery method Group 1: Topical metformin 30% cream applied once daily at night. Group 2: Triple Combination Cream (0.05% tretinoin, 2% hydroquinone, 0.01% fluocinolone acetonide) applied once daily at night. | <b>Timepoint</b>                                                                            |
| <b>Blinding (investigator's opinion)</b>      | Double blinded                                                                                                                                                                                                                                 | before intervention, 4week, 8 week, 12 week                                                 |
| <b>Blinding description</b>                   | Double blind study (both participant and data analyzer are blinded)                                                                                                                                                                            | <b>Method of measurement</b>                                                                |
| <b>Placebo</b>                                | Not used                                                                                                                                                                                                                                       | clinical examination and recording MASI score                                               |
| <b>Assignment</b>                             | Parallel                                                                                                                                                                                                                                       | <u>2</u>                                                                                    |
| <b>Other design features</b>                  |                                                                                                                                                                                                                                                | <b>Description</b>                                                                          |
| <b>Secondary Ids</b>                          | empty                                                                                                                                                                                                                                          | Incidence and severity of side effects (e.g., erythema, peeling, irritation, pigmentation). |
| <b>Ethics committees</b>                      |                                                                                                                                                                                                                                                | <b>Timepoint</b>                                                                            |
|                                               |                                                                                                                                                                                                                                                | 4 weeks, 8 weeks, 12 weeks                                                                  |
|                                               |                                                                                                                                                                                                                                                | <b>Method of measurement</b>                                                                |
|                                               |                                                                                                                                                                                                                                                | History and examination                                                                     |
|                                               |                                                                                                                                                                                                                                                | <b>Secondary outcomes</b>                                                                   |
|                                               |                                                                                                                                                                                                                                                | <u>1</u>                                                                                    |
|                                               |                                                                                                                                                                                                                                                | <b>Description</b>                                                                          |
|                                               |                                                                                                                                                                                                                                                | Quality of Life                                                                             |
|                                               |                                                                                                                                                                                                                                                | <b>Timepoint</b>                                                                            |
|                                               |                                                                                                                                                                                                                                                | Baseline, 4 week, 8 weeks, 12 weeks                                                         |
|                                               |                                                                                                                                                                                                                                                | <b>Method of measurement</b>                                                                |
|                                               |                                                                                                                                                                                                                                                | Melasma Quality of life score (MelasQoL)                                                    |

2

**Description**

Patient Satisfaction

**Timepoint**

4 weeks, 8 weeks, 12 weeks

**Method of measurement**

Subjective improvement giving scores from 1 to 4 ( none, mild, moderate, marked improvement)

3

**Description**

Recurrence

**Timepoint**

16th week

**Method of measurement**

clinical examination

**Intervention groups**

1

**Description**

Intervention group: Group A will be given 30% topical metformin at night

**Category**

Treatment - Drugs

2

**Description**

Intervention group: Group B will be given Triple Combination Cream (0.05% tretinoin, 2% hydroquinone, 0.01% fluocinolone acetonide) applied once daily at night.

**Category**

Treatment - Drugs

**Recruitment centers**

1

**Recruitment center**

**Name of recruitment center**

Combined Military Hospital, Quetta, Pakistan

**Full name of responsible person**

SAIMA ALI KHAN

**Street address**

Quetta

**City**

Quetta

**Postal code**

08762

**Phone**

+92 336 9947364

**Email**

saimaalikhan536x@gmail.com

**Sponsors / Funding sources**

1

**Sponsor**

**Name of organization / entity**

Combined Military Hospital, Quetta

**Full name of responsible person**

SAIMA ALI KHAN

**Street address**

Quetta

**City**

Quetta

**Postal code**

08762

**Phone**

+92 336 9947364

**Email**

saimaalikhan536x@gmail.com

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Combined Military Hospital, Quetta

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Combined Military Hospital, Quetta

**Full name of responsible person**

SAIMA ALI KHAN

**Position**

Assistant Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Dermatology

**Street address**

Quetta

**City**

Quetta

**Province**

Balochistan

**Postal code**

08762

**Phone**

+92 336 9947364

**Email**

saimaalikhan536x@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Combined Military Hospital, Quetta

**Full name of responsible person**

SAIMA ALI KHAN

**Position**

Assistant Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Dermatology

**Street address**

Quetta

**City**

Quetta

**Province**

Balochistan

**Postal code**

08762

**Phone**

+92 336 9947364

**Email**

saimaalikhan536x@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**

Combined Military Hospital, Quetta

**Full name of responsible person**

SAIMA ALI KHAN

**Position**

Assistant Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Dermatology

**Street address**

Quetta

**City**

Quetta

**Province**

Balochistan

**Postal code**

08762

**Phone**

+92 336 9947364

**Email**

saimaalikhan536x@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available